A US Food and Drug Administration (FDA) investigation of injection-site necrosis in some people who received the 23-valent pneumococcal vaccine has concluded that the benefits of the vaccine outweigh ...

Findings from a phase 3 study provided additional evidence that the first pneumococcal vaccine made specifically for adults ...

Please provide your email address to receive an email when new articles are posted on . There were less than 0.2 cases of injection site necrosis per million 23-valent pneumococcal vaccine doses.

Pneumococcal vaccine polyvalent; contains a total of 575mcg polysaccharides per 0.5mL; soln for IM or SC inj; contains phenol. Pneumovax 23 induces type-specific antibodies that enhance opsonization, ...

The Food and Drug Administration on Monday approved Merck’s new pneumococcal vaccine for adults 18 and older. The vaccine, which will be sold under the name Capvaxive, is designed to protect against ...

The FDA approved a 21-valent pneumococcal conjugate vaccine (Capvaxive) for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults, Merck announced on Monday. Specifically ...

WHITEHOUSE STATION, N.J., Aug 13, 2014 (BUSINESS WIRE) -- Merck MRK +1.47% , known as MSD outside of the United States and Canada, today provided the following statement regarding the U.S. Centers for ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of positive results from the Phase 1/2 study, V116-001, evaluating ...

In a time of confusion and inconsistent information, healthcare professionals want you to know that it’s not too late to get ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from two initial Phase 3 studies evaluating the safety, tolerability ...

This is a preview. Log in through your library . Journal Information PNAS is the world's most-cited multidisciplinary scientific serial. It publishes high-impact research reports, commentaries, ...